INSIGHTS ON CELL & GENE CLINICAL TRIALS

• Evolving Landscape Of Payer Coverage For CGTs: Trends And Insights

  Examine how proactive payer engagement and robust clinical evidence regarding comparative effectiveness and durability of response can overcome significant reimbursement barriers and enhance patient access.

• Accelerating Parkinson's Disease Clinical Research Through CHDR's Monocentre Recruitment Capabilities

  Centralized PD trials reduce variability, accelerate enrolment, and enable genetic stratification for targeted therapies. This streamlined model delivers high-quality data and faster timelines, helping sponsors move confidently from early-phase research to late-stage development.

• Navigating The Enrollment Bottleneck In Early Oncology Trials

  Slow oncology trial enrollment raises costs and delays progress. AI prescreening, patient-focused engagement, and early pharmacology studies help accelerate recruitment and optimize trial design.

• Why Flexible, Collaborative Distribution Partners Matter For CGTs

  Learn how collaborative distribution models manage reimbursement hurdles and complex delivery requirements to ensure patient access and long-term commercial success.

• 6 Key Implications Of EU Clinical Trials Regulation

  Centralized submissions, greater transparency, and stronger patient protections reshape EU clinical trials, impacting timelines, costs, and strategies for sponsors and CROs.

• Why We Need To Look To The Future Of Clinical Trials

  Explore how decentralized trial elements, community-focused site networks, and patient-centric infrastructure can improve recruitment, data quality, equity, and efficiency.

• How DCTs Can Shift The Pediatric Rare Disease Research Landscape

  DCT solutions are not just about bringing the trial to the patient’s home and reducing logistical burdens, but also strengthening the family-researcher connection.

• Reducing The Burden Of Patient Retention And Improving Continuity

  Immunology trials often place a sustained burden on participants. However, integrating Home Trial Support (HTS) into a Phase 3 immunology trial can help improve the overall study experience.

• Psychiatric Drug Development Renaissance: With Familiar Risks

  Emerging psychiatric therapies bring hope, but progress is fragile. Biomarker-driven, mechanism-first approaches help overcome biological, regulatory, and commercial barriers.

• Trailblazing Clinical Drug Development In Dermatology

  AI, imaging, and biomarkers are transforming trials, reducing subjectivity and improving sensitivity while enabling decentralized designs, faster timelines, and more precise insights.